Evotec's Collaboration Sparks Hope For Acute Kidney Injury Breakthroughs

Benzinga·06/25/2025 10:41:12

Listen to the news

Evotec SE (NASDAQ:EVO) shares are trading higher in the premarket session on Wednesday. This surge follows the company’s announcement that it has joined the NURTuRE-AKI consortium.

NURTuRE-AKI consortium is a collaboration aimed at developing an extensive patient database for acute kidney injury (AKI) research and therapeutic discovery.

The initiative, known as NURTuRE-AKI, will help Evotec identify core biological mechanisms behind AKI and propel the discovery of novel treatment options.

Also Read: Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch

Evotec will integrate this data into its E.MPD platform, a molecular-level database that consolidates clinical and omics information, to enhance precision medicine capabilities.

By collecting longitudinal data across multiple stages of patient treatment, researchers will be able to evaluate disease progression with unprecedented depth and accuracy.

NURTuRE-AKI will focus on patients most vulnerable to AKI, including those undergoing cardiac surgery and individuals transitioning from acute kidney injury to chronic kidney disease.

The project will gather samples of blood, urine, DNA, and tissue alongside medical data, forming what is expected to be the most comprehensive AKI cohort worldwide.

“NURTuRE-AKI offers a rare opportunity to uncover molecular targets and develop biomarkers that could accelerate breakthroughs in kidney care,” said Cord Dohrmann, Chief Scientific Officer of Evotec.

He emphasized the company’s commitment to finding collaborators aligned with this mission.

Elaine Davies, Director of Research Operations at Kidney Research U.K., expressed optimism about the partnership, noting the initiative’s potential to reshape how kidney diseases are diagnosed and treated.

Price Action: EVO shares are trading higher by 3.19% to $4.210 premarket at last check Wednesday.

Read Next:

P3 Reveals How Data Is Solving The Healthcare Crisis For Seniors

Photo via Shutterstock

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English